-
Je něco špatně v tomto záznamu ?
Chromium Supplementation Reduces Resting Heart Rate in Patients with Metabolic Syndrome and Impaired Glucose Tolerance
B. Nussbaumerova, H. Rosolova, M. Krizek, F. Sefrna, J. Racek, L. Müller, C. Sindberg,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, randomizované kontrolované studie
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2011-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- chrom aplikace a dávkování terapeutické užití MeSH
- dvojitá slepá metoda MeSH
- lidé MeSH
- metabolický syndrom farmakoterapie patofyziologie MeSH
- metabolismus lipidů účinky léků MeSH
- oxidační stres účinky léků MeSH
- porucha glukózové tolerance farmakoterapie patofyziologie MeSH
- poškození DNA účinky léků MeSH
- prospektivní studie MeSH
- srdeční frekvence účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- randomizované kontrolované studie MeSH
Chromium (Cr) is considered as an important mineral, involved in biochemical reactions in human metabolic pathways. Organically bound Cr supplementation has been suggested to improve glycemia especially in patients with type 2 diabetes mellitus, but there are conflicting reports on efficacy. Effect of Cr is not clear in prediabetes status. Seventy patients with metabolic syndrome and impaired glucose tolerance (IGT), who are observed and treated in the Center of Preventive Cardiology of the University Hospital in Pilsen, were included in the prospective, randomized, double-blind, and placebo-controlled clinical study. Effect of Cr-enriched yeast (200 μg of elementary Cr in the morning and 100 μg in the evening) on glucose, lipid metabolism, fat tissue hormones, oxidative stress, and DNA damage markers was analyzed. There were no significant changes in glucose and lipid parameters, oxidative stress, or other laboratory markers. Only resting heart rate was significantly reduced in patients treated by Cr yeast, reflecting reduced sympathetic activity. This could represent an important cardiovascular risk reduction in patients with high cardiometabolic risk.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033754
- 003
- CZ-PrNML
- 005
- 20181022125935.0
- 007
- ta
- 008
- 181008s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12011-017-1128-6 $2 doi
- 035 __
- $a (PubMed)28856601
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Nussbaumerova, Barbora $u Center of Preventive Cardiology, 2nd Medical Department, Medical Faculty in Pilsen and Faculty Hospital, Charles University Prague, Pilsen, Czech Republic.
- 245 10
- $a Chromium Supplementation Reduces Resting Heart Rate in Patients with Metabolic Syndrome and Impaired Glucose Tolerance / $c B. Nussbaumerova, H. Rosolova, M. Krizek, F. Sefrna, J. Racek, L. Müller, C. Sindberg,
- 520 9_
- $a Chromium (Cr) is considered as an important mineral, involved in biochemical reactions in human metabolic pathways. Organically bound Cr supplementation has been suggested to improve glycemia especially in patients with type 2 diabetes mellitus, but there are conflicting reports on efficacy. Effect of Cr is not clear in prediabetes status. Seventy patients with metabolic syndrome and impaired glucose tolerance (IGT), who are observed and treated in the Center of Preventive Cardiology of the University Hospital in Pilsen, were included in the prospective, randomized, double-blind, and placebo-controlled clinical study. Effect of Cr-enriched yeast (200 μg of elementary Cr in the morning and 100 μg in the evening) on glucose, lipid metabolism, fat tissue hormones, oxidative stress, and DNA damage markers was analyzed. There were no significant changes in glucose and lipid parameters, oxidative stress, or other laboratory markers. Only resting heart rate was significantly reduced in patients treated by Cr yeast, reflecting reduced sympathetic activity. This could represent an important cardiovascular risk reduction in patients with high cardiometabolic risk.
- 650 _2
- $a chrom $x aplikace a dávkování $x terapeutické užití $7 D002857
- 650 _2
- $a poškození DNA $x účinky léků $7 D004249
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a porucha glukózové tolerance $x farmakoterapie $x patofyziologie $7 D018149
- 650 _2
- $a srdeční frekvence $x účinky léků $7 D006339
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a metabolismus lipidů $x účinky léků $7 D050356
- 650 _2
- $a metabolický syndrom $x farmakoterapie $x patofyziologie $7 D024821
- 650 _2
- $a oxidační stres $x účinky léků $7 D018384
- 650 _2
- $a prospektivní studie $7 D011446
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Rosolova, Hana $u Center of Preventive Cardiology, 2nd Medical Department, Medical Faculty in Pilsen and Faculty Hospital, Charles University Prague, Pilsen, Czech Republic.
- 700 1_
- $a Krizek, Miroslav $u Center of Preventive Cardiology, 2nd Medical Department, Medical Faculty in Pilsen and Faculty Hospital, Charles University Prague, Pilsen, Czech Republic.
- 700 1_
- $a Sefrna, Frantisek $u Center of Preventive Cardiology, 2nd Medical Department, Medical Faculty in Pilsen and Faculty Hospital, Charles University Prague, Pilsen, Czech Republic.
- 700 1_
- $a Racek, Jaroslav $u Institute of Clinical Biochemistry and Hematology, Medical Faculty in Pilsen and Faculty Hospital, Charles University Prague, Pilsen, Czech Republic.
- 700 1_
- $a Müller, Ludek $u New Technologies for the Information Society, European Centre of Excellence, Faculty of Applied Sciences, University of West Bohemia, Pilsen, Czech Republic.
- 700 1_
- $a Sindberg, Christian $u Research Department, Pharma Nord ApS, Vejle, Denmark. cdsindberg@pharmanord.com.
- 773 0_
- $w MED00000737 $t Biological trace element research $x 1559-0720 $g Roč. 183, č. 2 (2018), s. 192-199
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28856601 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181022130441 $b ABA008
- 999 __
- $a ok $b bmc $g 1339582 $s 1030748
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 183 $c 2 $d 192-199 $e 20170830 $i 1559-0720 $m Biological trace element research $n Biol Trace Elem Res $x MED00000737
- LZP __
- $a Pubmed-20181008
